UNSPSC 51182019: Androstenedione

This classification denotes an anabolic steroid with the molecular formula C19H26O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 409J2J96VR, chemically known as 3,17-dioxoandrost-4-ene but generally known as androstenedione, which bears US NIH Compound Identifier 6128. European Medicines Agency schedules Androstenedione in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB12900MIG. As of Q4 2014, ANDROSTENEDIONE remains the US FDA Preferred Term for this commodity.

Androstenedione bears US NLM identifiers UMLS ID CL026907 and NCI Concept Code C2300. SMILES: O=C1C2(C(C3C(C4(C(=CC(=O)CC4)CC3)C)CC2)CC1)C..

UNSPSC 51182019 Androstenedione, a Commodity code, addresses the procurement of generic multi-source pharmaceuticals and over-the-counter products by state and local government entities through cooperative purchasing arrangements. State and local governments buy pharmaceutical manufacturing and supply services under this code, with vendors required to provide comprehensive product catalogs, maintain cGMP and DSCSA compliance, establish relationships with authorized wholesalers, and deliver products through established distribution channels. The primary issuing bodies are state procurement offices and multistate cooperative purchasing alliances administering agreements on behalf of participating state and local member agencies, including state departments, counties, cities, and other public entities within the member network.

The Minnesota Department of Administration's Office of State Procurement, administering the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued an RFP on January 20, 2026 (due March 26, 2026) to establish multiple pharmaceutical supply contracts serving participating state and local government facilities across Minnesota, Oregon, and other member jurisdictions. The solicitation requires vendors to supply identified pharmaceutical products with specific National Drug Codes through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with products available by May 15, 2026 and resulting contracts effective July 1, 2026. Evaluation is weighted heavily on price competitiveness (75 percent), with remaining criteria addressing fixed pricing, data format compliance, EDI capability, and acceptance of a 3 percent administrative fee. The contract runs two years for new responders with optional extensions, while incumbent amendments extend through June 30, 2028.